关键词: 三阴性乳腺癌, 非转移性乳腺癌, 免疫治疗, 联合治疗, 程序性死亡受体-1, 程序性死亡受体配体-1, 预测标记物

Abstract: Research progress of PD-1 and PD-L1 inhibitors in neoadjuvant therapy of early triple-negative breast cancer        ZHOU Si-cheng, XIN Ling, YE Jing-ming, et al. Department of Thyroid and Breast Surgery, Peking University First Hospital, Beijing 100034, China
Corresponding author: XIN Ling, E-mail: 07453@pkufh.com
Abstract    The expression level and activity of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC) patients were significantly higher than those of other breast cancer sub-types, providing potential for immunotherapy. Multiple clinical trials have shown that PD-1 and PD-L1 inhibitors have achieved excellent therapeutic results in the neoadjuvant phase of non-metastatic TNBC. In addition, in the neoadjuvant phase, low-intensity chemotherapy combined with immunotherapy or dual immunotherapy without chemotherapy has a good therapeutic prospect and may be a future development trend. Different from metastatic TNBC, the specificity and sensitivity of PD-L1 to predict the efficacy of neoadjuvant immunotherapy in non-metastatic TNBC are relatively low. In the future, it is necessary to combine other immune markers and refine the TNBC classification, to select patients who can benefit from immunotherapy in a targeted manner, further improve the therapeutic value of PD-1 and PD-L1 inhibitors, and achieve precise treatment of TNBC.

Key words: triple-negative breast cancer, non-metastatic breast cancer, immunotherapy, combination therapy, programmed death 1, programmed death-ligand-1, predictive markers